nDatalyze announces a Letter of Intent with Dr. Dale Stevens, Ph.D., Associate Professor, Department of Psychology, Faculty of Health, York University – November 14, 2023



nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) announces a Letter of Intent with Dr. Dale Stevens, Ph.D., Associate Professor, Department of Psychology, Faculty of Health, York University.


Calgary, Alberta – November 14, 2023

For Immediate Release – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) announces that on November 10, 2023, NDAT signed a Letter of Intent (“LOI”) with Dr. Dale Stevens, Associate Professor, Department of Psychology, Faculty of Health, York University, whereby Dr. Stevens has agreed to be the Principal Investigator for the machine-learning-logic/DNA aspect of NDAT’s previously announced Clinical Study. Dr. Stevens received his Ph.D. in Neuropsychology, with a Specialization in Neuroscience, from the University of Toronto. He conducted postdoctoral work in cognitive neuroscience at Harvard University (Cambridge, MA) as a Research Associate, then at the National Institute of Mental Health (Bethesda, MD) as a senior Research Fellow.

Dr. Stevens will be assisted by Amir Zarie, PhD Candidate, also from York’s Department of Psychology. The LOI contemplates a formal agreement within 30 days, which formal agreement is to include, but not be limited to, specification of the project, preparation of a Mitacs grant application, an assessment of NDAT’s existing YMI predictive mental health system (“YMI”) logic, integration of a DNA aspect into YMI, calibration of YMI, and submission of a paper to a peer-reviewed journal. Readers are advised that this aspect of the overall Clinical Study deals with the assessment and calibration of YMI’s existing predictive logic and the integration of DNA data, and that the psychiatric aspect is expected to involve a different PI(s) and a different institution(s) whereafter both aspects are to be combined in an enhanced YMI system. Negotiations with potential psychiatric PIs are ongoing. The Corporation will finance this project with existing cash reserves.

James Durward, CEO/CTO states: “The addition of Dr. Stevens and Amir to our Clinical Study team is a significant advance toward our goal of providing an advanced comprehensive tool designed to improve the way mental conditions are diagnosed and treated. For the clogged mental health system and the mental health crisis, I believe the time for machine-learning-based decision support tools is now.”



YMI uses evidence-based, objective data from whole life experiences to predict individual mental states over time and applies this knowledge towards a fuller understanding of how mental health develops and to improve mental wellbeing. YMI combines machine-learning with a proprietary Reference Database that contains >1200 person’s genetic expressions, childhood environment, habits, phobias, lived experiences and lifestyle to generate a personalized graphic report predicting an individual’s predisposition toward a variety of common mental conditions, both current and forward in time.



Dr. Keith Courtney, President (psychiatric aspects)
Email: [email protected]

James Durward, CEO&CTO (technical aspects)
Telephone: (403) 689-3901
Email: [email protected]

Website: www.ndatalyze.com

YMI Website: https://ymihealth.ca


Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.